D. E. Shaw & Co., Inc. Aurinia Pharmaceuticals Inc. Transaction History

D. E. Shaw & Co., Inc.

$125 Billion
Q2 2025

A detailed history of D. E. Shaw & Co., Inc. transactions in Aurinia Pharmaceuticals Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 341,540 shares of AUPH stock, worth $4.04 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

341,540

Previous 264,423 29.16%

Holding current value

$4.04 Million

Previous $2.13 Million 36.09%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$7.2 - $8.64 $555,242 - $666,290	77,117 Added 29.16%	341,540 $2.89 Million
Q1 2025 May 15, 2025	BUY	$7.55 - $8.77 $989,729 - $1.15 Million	131,090 Added 98.32%	264,423 $2.13 Million
Q4 2024 Feb 14, 2025	BUY	$6.75 - $10.44 $265,842 - $411,168	39,384 Added 41.92%	133,333 $1.2 Million
Q3 2024 Nov 14, 2024	BUY	$5.32 - $7.33 $42,852 - $59,043	8,055 Added 9.38%	93,949 $688,000
Q2 2024 Aug 14, 2024	BUY	$4.81 - $5.78 $19,971 - $23,998	4,152 Added 5.08%	85,894 $490,000
Q1 2024 May 15, 2024	SELL	$4.93 - $9.31 $53,342 - $100,734	-10,820 Reduced 11.69%	81,742 $409,000
Q4 2023 Feb 14, 2024	SELL	$7.13 - $9.49 $1.89 Million - $2.51 Million	-264,584 Reduced 74.08%	92,562 $832,000
Q3 2023 Nov 14, 2023	SELL	$7.77 - $12.27 $1.99 Million - $3.15 Million	-256,367 Reduced 41.79%	357,146 $2.78 Million
Q2 2023 Aug 14, 2023	BUY	$8.96 - $11.69 $970,000 - $1.27 Million	108,259 Added 21.43%	613,513 $5.94 Million
Q1 2023 May 15, 2023	BUY	$5.94 - $11.27 $2.37 Million - $4.5 Million	398,970 Added 375.38%	505,254 $5.54 Million
Q4 2022 Feb 14, 2023	BUY	$4.11 - $8.14 $26,497 - $52,478	6,447 Added 6.46%	106,284 $459,000
Q3 2022 Nov 14, 2022	SELL	$6.66 - $12.39 $91,395 - $170,027	-13,723 Reduced 12.08%	99,837 $751,000
Q2 2022 Aug 15, 2022	BUY	$8.95 - $12.8 $310,090 - $443,481	34,647 Added 43.91%	113,560 $1.14 Million
Q1 2022 May 16, 2022	SELL	$10.05 - $22.48 $1.1 Million - $2.46 Million	-109,420 Reduced 58.1%	78,913 $977,000
Q4 2021 Feb 14, 2022	SELL	$17.78 - $33.08 $2.59 Million - $4.81 Million	-145,536 Reduced 43.59%	188,333 $4.31 Million
Q3 2021 Nov 15, 2021	BUY	$10.93 - $23.55 $3.22 Million - $6.93 Million	294,258 Added 742.87%	333,869 $7.39 Million
Q2 2021 Aug 16, 2021	BUY	$10.0 - $14.52 $277,760 - $403,307	27,776 Added 234.69%	39,611 $513,000
Q1 2021 May 17, 2021	SELL	$12.3 - $18.73 $3.56 Million - $5.42 Million	-289,198 Reduced 96.07%	11,835 $154,000
Q4 2020 Feb 16, 2021	SELL	$12.94 - $16.05 $491,797 - $609,996	-38,006 Reduced 11.21%	301,033 $4.16 Million
Q3 2020 Nov 16, 2020	BUY	$13.19 - $16.66 $2.93 Million - $3.7 Million	222,073 Added 189.86%	339,039 $4.99 Million
Q2 2020 Aug 14, 2020	SELL	$14.12 - $18.33 $80,088 - $103,967	-5,672 Reduced 4.62%	116,966 $1.9 Million
Q1 2020 May 15, 2020	BUY	$11.34 - $21.46 $1.39 Million - $2.63 Million	122,638 New	122,638 $1.78 Million
Q4 2019 Feb 14, 2020	SELL	$3.88 - $21.42 $1.3 Million - $7.18 Million	-335,027 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$5.34 - $6.59 $311,177 - $384,019	-58,273 Reduced 14.82%	335,027 $1.79 Million
Q2 2019 Aug 14, 2019	SELL	$6.05 - $6.75 $937,132 - $1.05 Million	-154,898 Reduced 28.26%	393,300 $2.59 Million
Q1 2019 May 15, 2019	BUY	$6.06 - $7.64 $965,885 - $1.22 Million	159,387 Added 40.99%	548,198 $3.56 Million
Q4 2018 Feb 14, 2019	BUY	$5.08 - $6.83 $634,695 - $853,340	124,940 Added 47.35%	388,811 $2.65 Million
Q3 2018 Nov 14, 2018	BUY	$5.27 - $6.64 $782,062 - $985,369	148,399 Added 128.52%	263,871 $1.75 Million
Q2 2018 Aug 14, 2018	SELL	$5.06 - $6.36 $592,834 - $745,143	-117,161 Reduced 50.36%	115,472 $650,000
Q1 2018 May 15, 2018	BUY	$4.85 - $5.99 $1.13 Million - $1.39 Million	232,633 New	232,633 $1.21 Million

Others Institutions Holding AUPH

# of Institutions

248

Shares Held

62.5M

Call Options Held

1.03M

Put Options Held

666K

View Full List

About Aurinia Pharmaceuticals Inc.

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.68B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

More about AUPH

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account